Recent advances in the genomics and therapy of BCR/ABL1-positive and -negative chronic myeloproliferative neoplasms

• Type of Material: Article
• Authors: Tariq I. Mughal, Tufts University; Jason Gotlib, Stanford University; Ruben Mesa, University of Texas; Steffen Koschmieder, RWTH Aachen University; Hanna Khoury, Emory University; Jorge E Cortes, University of Texas; Tiziano Barbui, Papa Giovani XXIII Hospital and Research Center; Rüdiger Hehlmann, Universität Heidelberg; Michael Mauro, Memorial Sloan Kettering Cancer Center; Susanne Saussele, Universität Heidelberg; Jerald P. Radich, Fredreick Hutchinson Cancer Research Center; Richard A. Van Etten, University of California, Irvine; Giuseppe Saglio, Orbassano University Hospital; Srdnan Verstovek, University of Texas; Robert Peter Gale, Imperial College London; Omar Abdel-Wahab, Memorial Sloan-Kettering Cancer Center
• Language: English
• Date: 2018-04-01
• Publisher: Elsevier
• Publication Version: Author Accepted Manuscript (After Peer Review)
• Copyright Statement: © 2018 Elsevier Ltd. All rights reserved.
• License: Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International
• Final Published Version (URL): http://dx.doi.org/10.1016/j.leukres.2018.02.008
• Title of Journal or Parent Work: Leukemia Research
• ISSN: 0145-2126
• Volume: 67
• Start Page: 67
• End Page: 74
• Grant/Funding Information: The authors and the faculty members at both live events wish to thank Dr. Alpa Parmar for her organization skills, and Incyte Corporation, Novartis Oncology Global and Alpine Oncology Foundation for their support.
• Keywords: Mutation; Congresses as Topic; Myeloproliferative Disorders; Antineoplastic Agents; TFR; MPN; Cardiovascular Diseases; CALR; Chronic Disease; Epigenesis, Genetic; Cardiotoxicity; Mastocytosis; Humans; Fusion Proteins, bcr-abl; Calreticulin; Translational Medical Research; Protein Kinase Inhibitors; Cell Transformation, Neoplastic; Remission Induction; Mastocytosis, Systemic; CML; Staurosporine; Janus Kinase 2; JAK2 inhibitors
• Research Categories: Health Sciences, Oncology; Health Sciences, Medicine and Surgery

Abstract

This review is based on the presentations and deliberations at the 7th John Goldman Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN) Colloquium which took place in Estoril, Portugal on the 15th October 2017, and the 11th post-ASH International Workshop on CML and MPN which took place on the 6th-7th December 2016, immediately after the 58th American Society of Hematology Annual Meeting. Rather than present a resume of the proceedings, we have elected to address some of the topical translational research and clinically relevant topics in greater detail. We address recent updates in the genetics and epigenetics of MPN, the mechanisms of transformation by mutant calreticulin, advances in the biology and therapy of systemic mastocytosis, clinical updates on JAK2 inhibitors and other therapeutic approaches for patients with MPNs, cardiovascular toxicity related to tyrosine kinase inhibitors and the concept of treatment-free remission for patients with CML.